Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia
Why the study?
Does perivascularly delivered aFGF improve myocardial flow and left ventricular function in a porcine model of chronic myocardial ischemia?
Population
15 Yorkshire pigs subjected to Ameroid occluder placement on the left circumflex artery to induce chronic…
Comparison
Perivascularly administered genetically modified… vs EVAc polymer alone
Design
Preclinical
Follow-up
7 to 9 weeks
Authors
Discussion
Loading...
Member takes
Implication
Animal data suggest aFGF potential in chronic ischemia; hypothesis-generating, requiring human trials before any clinical consideration.
Structured PICO
Does perivascularly delivered aFGF improve myocardial flow and left ventricular function in a porcine model of chronic myocardial ischemia?
P
Population
15 Yorkshire pigs subjected to Ameroid occluder placement on the left circumflex (LCX) artery to induce chronic myocardial ischemia
I
Intervention
Perivascularly administered genetically modified acidic fibroblast growth factor (aFGF) in ethylene vinyl acetate (EVAc) polymer (10 micrograms)
C
Comparator
EVAc polymer alone
O
Outcome
Microsphere-determined coronary flow and global and regional left ventricular functionsurrogate
Perivascular delivery of aFGF improves myocardial perfusion and ventricular function in a porcine model of chronic ischemia, suggesting potential for therapeutic angiogenesis.
Cite This Study
López et al. (1998) studied this question.